

N.B. This is an unofficial translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text shall prevail.

Statement regarding the work of the nomination committee and reasoned statement for the nomination committee's proposal

In accordance with the procedures for appointing the nomination committee resolved by the annual general meeting 2021 the three largest shareholders in Isofol Medical AB, as well as a minority of shareholders representing more than 10 per cent of the votes, have appointed members of Isofol Medical AB's nomination committee. The nomination committee thereby consists of chairman Malin Björkmo (appointed by Handelsbanken Fonder) together with the members Lars Lind (appointed by Hans Enocson), Ulrik Grönvall (appointed by Swedbank Robur Fonder), Mats-Ola Palm (appointed by approx. 12 % of the votes) and Pär-Ola Mannefred (chairman of the board of directors), submits the following proposals.

The nomination committee initiated its work in November and has during the course of this work held a number of minuted digital meetings, as well as further informal discussions. The nomination committee has interviewed each of the board members and the chairman of the board of directors has given his overall assessment of the company's business, the work of the board of directors, its composition and the board members contributions in the board discourse. The nomination committee has also interviewed the company's management.

The nomination committee is of the opinion that it has a good overview of the board of directors' work. The board of directors is functioning well, and the work is carried on in a professional and efficient manner.

The nomination committee has based its proposal on in-depth discussions regarding competence, experience and background required of the members of the board of directors of Isofol Medical AB. Thereby, attention has been paid to the company's situation and future development, and especially the transition from pre-commercial to commercial phase. Independence and gender equality has also been reviewed as well as the suitability of the size of the board of directors. In preparation of its proposal regarding the composition of the board of directors, the nomination committee has applied the requirements in Section 4.1 of the Swedish Code of Corporate Governance to aim for diversity, breadth and gender balance on the board of directors.

As the chairman of the board of directors has informed that he would not be eligible for re-election at the annual general meeting, the nomination committee's work has been focused on recruiting a new chairman of the board of directors. The nomination committee formulated a requirement profile and retained the services of an external recruiting company to find suitable candidates satisfying the requirement profile.

The recruiting process resulted in the nomination committee being able to put forward a proposal to the annual general meeting of a chairman of the board of directors well satisfying the requirements regarding, among other, experience from the global health care industry, including commercialisation, negotiations and M&A.

The nomination committee proposes that Jan Törnell is elected chairman of the board of directors in Isofol Medical AB.

Jan Törnell

Born: 1960

Professional experience: Jan Törnell has extensive international experience from managerial positions within life science, for example as Vice President of Global Strategy at AstraZeneca Oncology & Infection. Jan Törnell has further held positions as professor of Physiology at Sahlgrenska University Hospital and as Docent of Physiology at University of Gothenburg. Today he holds board assignments in multiple boards for companies within the life science sector and works as an adviser regarding pharmaceutical projects.

Education: M.D. and PhD in Physiology from the University of Gothenburg.

Other board assignments: Jan Törnell is chairman of the board of Lidds AB and Glactone Pharma AB, a board member of Abliva AB and Innotext AB, where he also serves as CEO, and deputy board member of Lidds Pharma AB.

Shareholding in Isofol: –

Independence: Jan Törnell is independent in relation to the company and management, and independent in relation to major shareholders of the company.

The nomination committee's assessment is that the proposed board of directors is appropriate in consideration of the company's operations, current stage of development and general state of affairs, giving an appropriate composition both ensuring necessary continuity and providing the breadth of competence, experience, background and diversity that the company's operations and current stage of development requires. The nomination committee's opinion is that the proposed persons have the time and availability required to fulfil their assignments.

As regards gender breakdown of the board of directors, the proposal set forth by the nomination committee will not result in any changes. The proportion of female board members will remain unchanged at 25 per cent. The nomination committee considers the question of gender equality to be important and urges future nomination committees to keep actively working with gender equality.

The nomination committee has concluded that its proposal of board composition satisfies the independence requirement set forth by Nasdaq Stockholm and the Swedish Code of Corporate Governance.

The nomination committee has further assessed the fees to the board of directors as well as remuneration for committee work. The nomination committee's proposal for fees to the board of directors is based on responsibility, effort and qualification requirements for the board of directors of Isofol Medical AB as well as current remuneration levels in comparable companies.